How did NEO's revenue and expenses trend in Q4 2024?

Neogenomics (NEO) reported a net loss of $15.32 million in Q4 2024, with operating expenses amounting to $7.97 million and research and development (R&D) expenses at $6.81 million. The company's revenue by business is not available, but the negative net income indicates a challenging financial period. |code|Ticker|Name|Date|Business Composition|Revenue By Business|market_code| |---|---|---|---|---|---|---| |NEO|NEO.O|Neogenomics|20240101-2024|Self-Pay|681000|186| |NEO|NEO.O|Neogenomics|20240101-2024|Advanced Diagnostics|6.686E7|186| |NEO|NEO.O|Neogenomics|20240101-2024|Advanced Diagnostics|4.4819E7|186| |NEO|NEO.O|Neogenomics|20240101-2024|Advanced Diagnostics|2.1705E7|186| |NEO|NEO.O|Neogenomics|20240101-2024|Advanced Diagnostics|2.1705E7|186| |NEO|NEO.O|Neogenomics|20240101-2024|Clinical Services|1.34535E8|186| |code|Ticker|Name|Date|R&D Expenses|Operating Expenses|Net Income|Advertising and Marketing Expenses|market_code| |---|---|---|---|---|---|---|---|---| |NEO|NEO.O|Neogenomics|2024 Q1|7620000||-2.7061E7||186| |NEO|NEO.O|Neogenomics|2024 Q2|7886000||-1.8642E7||186| |NEO|NEO.O|Neogenomics|2024 Q3|7684000||-1.7699E7||186| |NEO|NEO.O|Neogenomics|2024 Q4|7969000||-1.5324E7||186|